JPRN-UMIN000016507已完成2 期
A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancer - A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) EGFR mutation with T790M in exon 20 2) Uncontrolled symptomatic brain metastasis 3) Hemoptysis 4) Bleeding tendency 5) Use of antithrombotic agents 6) Evidence of tumor invading major blood vessel 7) Cavitated tumor 8) Thrombosis 9) Interstitial pneumonia or pulmonary fibrosis on imaging 10) Gastrointestinal disorder 11) Uncontrollable pleural effusion , ascites or pericardial effusion 12) Past given the radiation therapy for chest 13) Active double cancer 14) Severe complication 15) History of severe allergy
研究者
相似试验
已完成
不适用
A phase II study of erlotinib plus bevacizumab in chemo-naive patients aged 75 or older with advanced non-squamous non-small-cell lung cancer harboring sensitive EGFR gene mutations(HSR1501)Advanced non-squamous non-small-cell lung cancerJPRN-UMIN000016904Department of Internal medicine, second division, Hamamatsu Univ. School of Medicine26
尚未招募
2 期
A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000012514Department of Respiratory Medicine, Kumamoto University Hospital16
已完成
2 期
Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-squamous, non-small cell lung cancer harboring activating EGFR mutationsadvanced EGFR mutation-positive non-squamous non-small cell lung cancerJPRN-UMIN000015467Department of Thoracic Oncology Osaka Medical Center for Cardiovascular diseases20
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)on-Small Cell Lung CancerJPRN-UMIN000006459Kyushu University38
招募中
2 期
Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)on-Small Cell Lung CancerJPRN-UMIN000006457Kyushu University30